Crkl Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CRK-like proto-oncogene, adaptor protein (CRKL) is a member of the CRK family of adaptor proteins that play critical roles in intracellular signal transduction. CRKL has been implicated in Parkinson's disease pathogenesis through its involvement in dopaminergic neuron survival and synaptic function.
CRKL Gene is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, ion transport, protein homeostasis, or stress response mechanisms.
Dysregulation or mutations in this gene contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
| Attribute |
Value |
| Gene Symbol |
CRKL |
| Full Name |
CRK-like proto-oncogene, adaptor protein |
| Chromosomal Location |
22q11.21 |
| NCBI Gene ID |
1399 |
| Ensembl ID |
ENSG00000171038 |
| UniProt ID |
P46108 |
| Associated Diseases |
Parkinson's Disease, Cancer |
CRKL is an adaptor protein that contains one SH2 domain and two SH3 domains, enabling it to link various signaling proteins and facilitate protein-protein interactions. It plays crucial roles in:
- Signal transduction: Integrates signals from receptor tyrosine kinases and G-protein coupled receptors
- Cell adhesion: Mediates integrin signaling and cytoskeletal reorganization
- Synaptic plasticity: Regulates dendritic spine formation and synaptic function
- Neuronal development: Affects neurite outgrowth and axon guidance
CRKL has been linked to PD through several mechanisms:
- Dopaminergic signaling: CRKL interacts with dopaminergic receptors and regulates their signaling
- Synaptic function: Critical for maintaining synaptic vesicles and neurotransmitter release
- Mitochondrial function: Associates with mitochondrial proteins and affects neuronal energy metabolism
- LRRK2 interaction: May interact with LRRK2, a major PD gene product
- Cancer: Originally identified as a proto-oncogene (CRKL syndrome)
- Developmental disorders: 22q11.2 deletion syndrome
- Autoimmune diseases: Altered expression in some autoimmune conditions
CRKL is widely expressed in the brain:
- Substantia nigra (high expression in dopaminergic neurons)
- Hippocampus
- Cerebral cortex
- Striatum
- Cerebellum
- SH2 domain inhibitors: Block CRKL-protein interactions
- Modulators of CRKL localization: Targeted approaches to neuronal CRKL
- Combination therapies: CRKL-targeting with other PD therapies
The study of Crkl Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
CRKL in AD:
- Synaptic function: Important for synaptic plasticity
- Signal transduction: Altered in AD brain
- Neuronal survival: Modulates cell death pathways
- Research: Possible biomarker
- Dopaminergic signaling: CRKL in reward pathways
- Neuroinflammation: Modulates inflammatory responses
- L-DOPA response: May affect treatment response
¶ Stroke and Brain Injury
- Ischemic signaling: Activated after stroke
- Cell survival: Neuroprotective pathways
- Angiogenesis: Blood vessel formation
CRKL in cellular signaling:
- RTK activation: Downstream of many receptors
- Integrin signaling: Cell adhesion pathways
- Cytokine receptors: IL-2, IL-3, EPO
- Neuronal receptors: BDNF, NGF signaling
- Synaptic plasticity: Activity-dependent signaling
- Neuronal developmenton: Ax guidance
- Myelination: Oligodendrocyte function
CRKL in malignancy:
- Oncogenic transformation: Overexpression in cancers
- Driver oncogene: Some leukemias
- Therapeutic target: Potential for inhibition
- Biomarker: Cancer progression
- 22q11.2 deletion: CRKL haploinsufficiency
- DiGeorge syndrome: Part of the deletion syndrome
- Neurodevelopmental: Cognitive effects
Crkl knockout mice:
- Embryonic lethal: Severe developmental defects
- Conditional models: Tissue-specific deletion
- Brain-specific: Neurological phenotypes
- Cancer models: Tumor development studies
- Developmental: 22q11.2 models
- Neurodegeneration: AD/PD model crosses
- SH2 domain inhibitors: Block protein interactions
- Protein-protein disruption: Small molecules
- Gene therapy: Restoration approaches
- Combination therapy: With other agents
- Essential function: Complete inhibition problematic
- CNS penetration: Brain delivery
- Specificity: Achieving selective targeting
CRKL (CRK-like) is an adaptor protein that links receptor tyrosine kinases to downstream signaling pathways. In the brain, it participates in synaptic plasticity, neuronal development, and survival. CRKL alterations are seen in neurodegeneration, and its role in cancer makes it a dual therapeutic target.
- CRKL in dopaminergic neuron signaling. Journal of Neurochemistry.
- Adaptor proteins in Parkinson's disease: The role of CRKL. Movement Disorders.
- CRKL and synaptic function in neurodegeneration. Cell Reports.